Evaluating malaria elimination strategies in military forces in Cambodia: a cluster-randomized clinical trial comparing monthly

³ prophylaxis with focused screening and treatment

4

5 Mariusz Wojnarski¹, Sidhartha Chaudhury^{1§}, Threechada Boonchan¹, Rathvicheth Bun³, Soklyda Chann³, Panita

6 Gosi¹, Kin Soveasna², Sokhun Song¹, Nillawan Buathong¹, Mali Ittiverakul¹, Sabaithip Sriwichai¹, Montri Arsanok¹,

7 Worachet Kuntawunginn¹, Piyaporn Saingam¹, Chaiyaporn Chaisatit¹, Alongkot Ponlawat¹, Thanyalak Fansiri¹,

8 Pattaraporn Vanachayangkul¹, Boonsong Jaichapor¹, Muth Sinoun³, Char Meng Chuor³, Thay Kheangheng³, Mary

9 So², Elizabeth Wanja¹, Silas Davidson¹, Michele Spring¹, Huy Rekol³, Lek Dysoley^{3,7}, Kong Saly², Jeffrey R.

10 Livezey¹, Jessica T. Lin⁴, Philip L. Smith^{1,8}, Prom Satharath², Jessica E. Manning^{6,9}, Somethy Sok^{1*}, David L.

11 Saunders^{1,5*}

12 1. Walter Reed Army Institute of Research - Armed Forces Research Institute of Medical Sciences, Bangkok,

- 13 Thailand
- 14 2. Ministry of National Defense, Department of Health, Phnom Penh, Cambodia
- 15 3. National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia
- 16 4. University of North Carolina School of Medicine, Chapel Hill, NC, United States
- 17 5. Uniformed Services University School of Medicine, Bethesda, MD, United States
- 18 6. International Center of Excellence in Research, National Institute of Allergy and Infectious Disease, National
- 19 Institutes of Health, Phnom Penh, Cambodia and Laboratory of Malaria and Vector Research, NIH, Bethesda, MD
- 20 7. School of Public Health, National Institute of Public Health, Phnom Penh, Cambodia
- 21 8. Defense Health Agency, Falls Church, VA, United States
- 22 9. Sanofi-Pasteur, Bethesda, MD, United States
- 23 * The Authors indicated contributed to this manuscript equally.
- 24 **§Corresponding author:** Sidhartha Chaudhury, sidhartha.chaudhury.mil@health.mil
- 25
- 26
- 27
- 28

29 Abstract

30

31 Background

32 Identifying effective malaria elimination strategies for remote forested regions in Southeast Asia is 33 challenging given limited resources. In this study, two malaria elimination strategies were evaluated in 34 partnership with the Royal Cambodian Armed Forces - monthly malaria prophylaxis (MMP) and focused 35 screening and treatment (FSAT).

36 Methods

Eight primarily military clusters (1,050 volunteers total) along the Cambodian-Thai border were randomized to 3 months of MMP or FSAT with monthly malaria testing by RDT, PCR, and microscopy for six months. Clusters were sub-randomized to permethrin treated (ITU) or sham water-treated clothing (sITU). Volunteers in MMP clusters were given three full monthly dihydroartemisinin-piperaquine (DP) treatment courses with 12 weekly 22.5mg primaquine. Volunteers in FSAT clusters were treated with appropriate first-line antimalarials if malaria-positive by microscopy or PCR.

43 **Results**

Pf positivity in MMP clusters was reduced by 90% (10% at enrollment to 1% at 6 months; absolute risk 44 45 reduction (ARR) 9%) at 6 months. However, 32% of Pf cases treated with DP as MMP at baseline recrudesced, requiring rescue treatment at 1 month with artesunate-mefloquine. Pf positivity in FSAT 46 clusters declined 66% over 6 months (7.6% to 2.7%; ARR 4.9%). MMP reduced Pv positivity from 9% to 47 0% at 3 months, but Pv rebounded to 6.7% at 6 months. FSAT failed to significantly reduce Pv positivity 48 during the study. The 22.5mg weekly primaquine MMP regimen was safe, even for the 15% of volunteers 49 50 with G6PD-deficiency. Those wearing ITU had additional Pv parasitemia reductions compared to sITU in 51 the FSAT but not MMP groups. PCR was more sensitive than microscopy and RDT for detecting both 52 species.

53 Conclusions

54 MMP was safe, and superior to FSAT to reduce *Pf* and *Pv*, suggesting greater utility to achieve malaria 55 elimination in Cambodia. Low dose (22.5mg) weekly primaquine was a safe adjunct in this setting, even 56 for those with G6PD-deficiency. Permethrin-treated clothing further reduced *Pv* parasitemia for FSAT but 57 not MMP. MMP may be more easily scaled to eliminate malaria. The military may provide substantial 58 support for regional elimination efforts.

59

60 Introduction

61 Intensive containment and control efforts have successfully reduced malaria prevalence in the Greater Mekong Subregion (GMS). However, multi-drug resistant (MDR) Plasmodium falciparum (Pf) 62 63 remains endemic in border areas of Cambodia and Thailand, with confirmed spread to neighboring 64 countries [1]. In Southeast Asia, declining efficacy of artemisinin combination therapies (ACT) has occurred within a few years of their introduction as first-line therapies [2-5]. Concerns that 'untreatable' 65 66 malaria may emerge, combined with relatively low burden favors an aggressive approach to elimination 67 in the region. This has been codified in commitments by ASEAN leaders in 2018 and the World Health Organization in 2022 to a goal of regional elimination by 2025 for Pf and by 2030 for Plasmodium vivax 68 69 (Pv) [6-8]. Unfortunately, the spread of MDR Pf has outpaced development of new antimalarials, limiting 70 pharmacological approaches to elimination [9]. Malaria elimination is also particularly challenging 71 among mobile populations with occupational exposures occurring in forested areas to include the military [10, 11]. Populations residing or working in forested border areas carry a significant MDR malaria 72 73 burden in the GMS [12, 13]. There is currently no consensus on how elimination will be achieved for hard-to-reach mobile populations disproportionately affected by malaria [10, 11]. Multiple approaches 74 75 have been suggested, most requiring further evaluation [14]. Two approaches are typically proposed for malaria elimination in this region. The first is 'mass 76

drug administration' (MDA) and the second is 'focused screening and treatment' (FSAT) where entire
communities are evaluated and positive members receive treatment. MDA involves mandatory treatment

ranging from focal areas of outbreak to entire endemic communities. While there have been a large number of MDA studies conducted over the past 70 years, a recent systematic review identified numerous challenges in comparing studies of varying designs. MDA studies are often complicated by a lack of welldefined objectives [15]. MDA if often thought to be the more effective approach because of lower costs, simplified logistics and better outcomes despite known limitations that includes potential added risk to those without malaria. Unless sustained, MDA has had limited effectiveness in practice among diverse settings [16].

Prior studies identified factors associated with MDA success. These include achieving at least 86 80% population coverage, directly observed treatment (DOT), strong community engagement, and the use 87 88 of 8-aminoquinolines, particularly in Pv transmission settings [17, 18]. However, increasing prevalence of 89 MDR Pf may compromise MDA effectiveness, and repeated administrations may be necessary in high 90 transmission areas [19]. Finally, the use of compulsory anti-malarial treatment courses with associated 91 side-effects in healthy individuals raised ethical concerns for MDA in low-transmission settings. Despite 92 documented logistical challenges to implementation [20], an FSAT approach was thought to be a more 93 ethical though less effective alternative [21]. The FSAT and MDA approaches have not been evaluated 94 head-to-head in Cambodia, and there have been few studies conducted in hard-to-reach mobile populations, particularly the military [22]. Despite widespread use of malaria chemoprophylaxis by 95 96 Western militaries deploying to malaria endemic areas, this approach has not been systematically 97 evaluated nor widely adopted by militaries in Southeast Asia.

Diagnostic challenges also influence potential approaches. Rapid diagnostic tests (RDTs) are a
practical option to screen large populations but low sensitivity limits their ability to identify individuals
with subclinical infections and low parasitemia in areas approaching malaria elimination [19, 23, 24].
Significant numbers of asymptomatic cases may be missed in the FSAT approach unless more sensitive
methods such as PCR are employed [23]. PCR offers greater sensitivity and specificity but is expensive,
difficult to implement in austere locations, and does not detect the latent stages of *P. vivax* [25]. Even
without PCR, the amount of laboratory support and follow-up required to perform adequate systematic

FSAT on even a monthly basis is significant [20]. The other key diagnostic challenge is detecting G6PD-105 106 deficiency for those being administered 8-aminoquinolines. While several new G6PD tests have been 107 field tested in Southeast Asia, the gold standard quantitative testing remains expensive and difficult to 108 implement in austere environments [26]. 109 Operational costs and complexities for various elimination approaches are poorly quantified and may be underestimated. The optimal approach has yet to be defined but is likely to include vector control 110 111 measures in addition to drug therapy. Vector control measures such as indoor residual insecticide spraying (IRS) and the use of insecticide treated nets (ITNs) have been widely employed in Cambodia. 112 However, the efficacy of vector interventions suitable for militaries, including use of insecticide-113 114 impregnated uniforms and various forms of personal and spatial repellants, remain untested in field settings, particularly against disease endpoints in clinical trials. The contribution of insecticide resistance 115 116 to effectiveness also remains unclear [27]. The potential roles of militaries, thought to be a potent force 117 for elimination, have yet to be evaluated [28]. The present study aimed to answer some of the key outstanding questions outlined above to 118 define optimal approaches to malaria elimination. The US Army Medical Component of the Armed 119 120 Forces Research Institute of Medical Sciences (AFRIMS) conducted a cluster-randomized interventional 121 malaria elimination trial in partnership with the Royal Cambodian Armed Forces (RCAF) and National Center for Parasitology Entomology and Malaria Control (CNM) in Cambodia. The study aimed to 122 123 quantify the relative safety and effectiveness of two major interventional approaches to malaria elimination in this region: (1) monthly malaria prophylaxis (MMP) using 3 monthly 3-day treatment 124 courses of dihydroartemisinin-piperaquine (DP) and a weekly low dose of 22.5mg of primaquine, and (2) 125 126 focused screening and treatment (FSAT) of only those found to be either microscopy or PCR malaria 127 positive using the current first-line antimalarials recommended for Pf and Pv respectively. The additive 128 effects of insecticide-treated uniforms (ITU) on malaria prevalence were also assessed by comparing to 129 sham-treated uniforms or clothing (sITU) to prevent infectious mosquito bites.

131 Materials and Methods

132	Details of the study protocol and methods have been previously published [29]. The overarching
133	goal of this pilot elimination study was to increase Cambodian malaria control program capabilities to
134	diagnose, prevent, and treat malaria with a focus on at-risk military personnel. To do so, a scalable
135	military malaria elimination 'unit of action' was established at the provincial level. The Unit primarily
136	relied on medical personnel stationed with volunteers to monitor for disease and provide DOT. The
137	military elimination unit was staffed by 187 RCAF personnel trained and supplied by the AFRIMS-CNM
138	research team. This team included 170 medics assigned to individual units responsible for day-to-day
139	treatment and follow-up during the study. Medics were divided roughly evenly between clusters with
140	centrally located administrative, laboratory and IT support staff.
141	The primary objective of the study was to compare the effectiveness of two elimination
142	approaches. A cluster-randomized, open label interventional study was conducted in eight military
143	residential clusters on the Cambodia-Thai border. Each cluster included approximately 120 individuals.
144	The study aimed to determine feasibility to achieve significant reductions in malaria prevalence using a
145	combination of available interventions. There were four clusters where reactive screening and treatment
146	(FSAT) was employed. In FSAT clusters, malaria was confirmed by real-time PCR, with those found
147	positive by PCR treated with currently recommended medications according to national treatment
148	guidelines. The other four clusters received monthly malaria prophylaxis (MMP) with
149	dihydroartemisinin-piperaquine (DP) and 12 weekly doses of low-dose primaquine (PQ) (see Study
150	Interventions). Clusters were sub-stratified a priori based on low or high malaria transmission assessed
151	through routine public health surveillance prior to the study (see Table 1). Clusters were further sub-
152	randomized to wear of permethrin (ITU) or sham-treated (sITU) uniforms or clothing while in forested
153	areas.

155 Study population

156	Inclusion criteria included: 1) Volunteers 18-65 years of age and their dependents \geq 2 years of
157	age, to include military and eligible Cambodian civilians eligible for care at an RCAF facility; 2) Able to
158	give informed consent/assent; 3) Residing in the selected study areas, 4) Available for monthly follow-up
159	for the 6-month study duration; 5) Agreed not to seek initial outside medical care for febrile illness unless
160	referred by the study team; and 6) Authorized by the local Commander to participate in the study if on
161	active military duty.
162	Exclusion criteria included: 1) Known allergic reaction or contraindication to interventions to be
163	used to include dihydroartemisinin-piperaquine, artesunate-mefloquine, or primaquine; 2) Pregnant or

164 lactating females, and females of childbearing age unwilling to use acceptable forms of contraception

during the study. Study assessments took place in RCAF facilities near the Cambodia-Thai border.

166

167 Cluster randomization, allocation and blinding

168 The eight community clusters were randomized to either MMP or FSAT groups, using time and 169 region-blocked randomization. This ensured that randomized clusters were geographically distinct, and 170 that treatment (MMP vs. FSAT) and uniform conditions (ITU vs. sITU) were evenly distributed among high and low transmission areas. There were four clusters in high and four in low endemicity areas. 171 172 Volunteers meeting enrollment criteria received either permethrin-treated uniforms (ITUs) or sham (water-treated) uniforms or civilian clothing as appropriate (sITUs). Clothing was treated according to 173 174 cluster assignment in single-blind fashion with the volunteer, but not the investigators, blinded to 175 assignment. Diagnostic microscopists were blinded to each other's readings and to study arm 176 assignments. The study design in shown in Figure 1. 177 178



180

181

182 Figure 1. Study design and timeline. All volunteers were screened for malaria with monthly malaria RDT, 183 microscopy and PCR testing. During the three-month intervention phase, volunteers in the MMP treatment arm 184 received regularly scheduled treatment with a full monthly DP treatment course and a weekly dose of 22.5mg primaquine regardless of malaria positivity for a total dose of 270 mg. Volunteers in the FSAT arm only received 185 186 treatment if found to be malaria-positive by microscopy or PCR. All volunteers in the study were screened monthly 187 for three additional months or when symptomatic with RDT, PCR and microscopy and treated for malaria if positive. Treatment with standard-of-care medications was given if positive by microscopy or PCR within 24-48 188 189 hours. Standard doses of PQ were used per national treatment guidelines in the FSAT arm.

190

191 Recruitment

Sites selected were based at military units willing to participate in the study and authorized to do 192 so by their respective Command authorities. Authorization was granted on a collective basis to military 193 personnel at each participating cluster prior to selection. Individuals at each site were enrolled based on 194 willingness to participate, and authorization for military personnel by their supervisor. However, the 195 Chain of Command was not involved in the enrollment process nor permitted to encourage or order 196 197 soldiers to participate in the study. Independent civilian ombudsman were present during consent and 198 enrollment to minimize undue influence among participants. Study sites were stratified a priori into high 199 and low malaria transmission areas based on internal RCAF malaria surveillance data from prior years. 200

201 Study Procedures

202	Following informed consent or parental consent with assent by minors, all subjects underwent
203	baseline assessments including a history and physical exam, complete blood count, and malaria diagnostic
204	testing. Glucose 6-phosphate dehydrogenase (G6PD)-deficiency screening was assessed using FDA-
205	approved quantitative testing methods (Trinity Biotech, Ireland). Malaria diagnostics included a rapid
206	test (SD BIOLINE Malaria Ag Pf/Pv malaria antigen or MALACHECK Ag pLDH/HRP2), microscopy
207	and molecular testing with species-specific PCR using previously described methods [29]. A threshold
208	of <35 PCR replication cycles was used to define positive results for malaria. The study consisted of a
209	three-month intervention period with MMP or FSAT, followed by a three-month follow-up period, during
210	which all volunteers continued monthly screening and treatment.
211	Malaria treatment was administered according to 2016 Cambodian National Treatment
212	Guidelines (NTG). Children <13 years old were not treated with PQ and had only finger stick blood
213	collections for malaria diagnostics. All volunteers with blood-stage parasitemia by light microscopy were
214	followed to clinical symptom resolution with two negative blood smears at least one week apart. If
215	volunteers were only PCR positive, they were evaluated again the following month to ensure clearance.
216	Recurrent cases of Pf were evaluated with molecular genotyping of MSP-1, MSP-2, and GLURP allelic
217	variants to distinguish recrudescence from reinfection [30].
218	

219 Study Interventions

Starting at enrollment, volunteers in the MMP group received 3 monthly three-day courses of fixed-combination DP tablets (Doucotexcin, Holley Pharmaceuticals, China) containing 40 mg of DHA and 320mg of piperaquine phosphate (PIP) during the intervention. All MMP volunteers age \geq 13 years also received 12 weekly PQ 22.5mg tablets (270 mg total dose) to prevent malaria transmission and *Pv* relapse. MMP participants that were found to be initially positive by PCR at enrollment received their first scheduled course of DP with the prescribed MMP regimen. However, MMP volunteers subsequently

found to be parasitemic by PCR or microscopy during follow-up were treated with standard-of-care antimalarials following national treatment guidelines (NTG). Volunteers in the MMP group who received rescue treatment following NTG, were treated with their regularly scheduled MMP regimen with DP on next monthly follow up, and while weekly low dose primaquine was continued on schedule without interruptions.

During the intervention period, all participants in FSAT clusters were screened monthly by RDT, 231 microscopy and PCR and treated following national guidelines if positive by microscopy or PCR. All 232 volunteers in FSAT clusters with parasitemia by PCR or microscopy were treated following the 2016 233 234 Cambodia National Treatment Guidelines. Pf-positive volunteers and those with mixed-species infections 235 received a full 3-day treatment course of artesunate and mefloquine (ASMO, Guilin Pharmaceutical Co 236 Ltd, Guilin, China) with a single low 15mg PQ dose (Government Pharmaceutical Organization, 237 Bangkok, Thailand). Pv-positive volunteers received a full 3-day treatment course of DP plus 15mg PQ 238 daily for 14 days to prevent relapse. G6PD-deficient Pv-positive volunteers received 8 weekly 45 mg 239 doses of PQ. The intervention and follow-up period used the same intervention for FSAT subjects. The 240 follow-up period for the MMP volunteers mirrored the FSAT intervention and follow-up period, 241 reflective of the NTG. All treatment was administered as Directly Observed Therapy (DOT) by RCAF medical personnel on the study team. 242

Participants were provided with outer garments to wear in forested areas prior to study start.
These included civilian clothing or military uniforms as appropriate. Garments were pre-treated with
insecticide by the study team prior to distribution using a single application of 40% permethrin Individual
Dynamic Absorption kits (NSN 6840-01-345-0237; U.S. Army) to produce treated clothing (ITU) or
water to produce sham-treated clothing (sITU). According to the product label, permethrin treatment was
designed to withstand 30 washings.

249

250 Statistical Analysis

251	Detailed description of the statistical plan is outlined in the prior study protocol publication [29].
252	In brief, the primary study endpoint the absolute risk reduction (ARR) based on the proportion of
253	volunteers in each arm with PCR-corrected absence of parasitemia at the end of 6 months using an
254	Intention-to-Treat analysis. Power analysis to determine the minimum sample size for the study assumed
255	a conservative value of 0.4 for the intra-class correlation coefficient (ICC). It was determined at least 78
256	individuals were required to achieve 80% power to detect a two-fold reduction in the ARR for MDA over
257	FSAT with an α =0.05. ARR was based on the proportion of malaria-free volunteers at six months [31].
258	As the number of available clusters was limited for practical reasons, a total of eight clusters with 80 to
259	140 volunteers per cluster was determined to be sufficient for this pilot study.
260	Demographic, epidemiological, and laboratory data were summarized at baseline and follow-up.
261	All enrolled volunteers were included in the database for primary endpoint analysis. The safety analysis
262	database included all volunteers who received at least one dose of study drug. T-tests and chi-square tests
263	were used to assess the statistical significance of differences in two means (including log-transformed) or
264	proportions, respectively. Confidence limits (95%) for means, geometric means, and proportions were
265	calculated. A mixed-effects logistic regression model was used to assess the role of treatment group
266	(MMP vs. FSAT), insecticide-treated uniforms (ITU vs. sITU), cluster regional endemicity (low vs. high),
267	and parasitemia at enrollment (positive vs. negative) on the likelihood of a Pf or Pv infection during the 6
268	month study period. Random effects were modeled at the cluster level. Time to event data was
269	summarized using Kaplan-Meier plots. The log-rank test was used to assess the statistical significance of
270	differences between the treatment groups.
271	
272	Ethics Statement

273 The trial was approved by the Walter Reed Army Institute of Research Institutional Review
274 Board (WRAIR IRB, Protocol number, WR2211) and the National Ethics Committee for Health Research

275 (NECHR) in Cambodia. The study was registered on Clinicaltrials.gov prior to enrollment

- 276 (NCT02653898).
- 277

278 Results

- 279 Enrollment and Study Follow up
- Of the 1,114 volunteers residing in the 8 selected clusters who were screened, 1,050 enrolled into 280 281 the study (Figure 2). This corresponded to 94.3% overall coverage in the population studied, ranging 282 from 89-97% coverage within individual clusters. The first subject was enrolled in January 2016 and the 283 last subject follow-up was completed in August 2016. There were 534 volunteers in four clusters assigned to MMP (264 received ITU and 270 sITU) and 516 volunteers in four clusters assigned to FSAT (240 284 received ITU and 276 sITU). Among enrolled volunteers, 75.8 % (796/1050) were military personnel, 285 286 12.8% (134/1051) were non-military adults, and 11.4% (120/1050) were children < 18 years old. All volunteers identified ethnically as Khmer, and 84.3% (885/1050) of the population were male. At six 287 288 months follow up, 90.1% (485/534) in MMP and 86.0% (443/516) in FSAT groups completed all study 289 follow-up (Supplemental Table 1). Overall, only 11% (124/1050) withdrew from the study before 290 completing all procedures, generally due to geographic reassignment or to new duties which precluded 291 continuation of follow up.



292

Figure 2. CONSORT Flow Diagram. Volunteers were randomized to one of 8 geographically isolated unit-based
 clusters. There were a total of 4 clusters for MMP (green) and another 4 clusters for FSAT (orange) treatment
 interventions. Half of the volunteers assigned to MMP and FSAT were also treated with insecticide treated uniforms
 (ITUs). Total follow-up was 180 days after enrollment. Most volunteer withdrawals and losses to follow-up were
 due to movement outside the study areas.

298

299 Cluster composition at baseline is shown in **Table 1**. The study was designed to ensure balanced 300 representation of all conditions (treatment, uniform, and endemicity) across the clusters within the study. Baseline Pv prevalence was 8.4% (45/534) in the MMP groups compared to only 2.7% (13/516) in FSAT 301 clusters. Pf prevalence for both arms was comparable at baseline (Pf MMP = 62/534 = 9.7%; Pf FSAT = 302 303 42/516 = 8.1%). PCR-confirmed malaria prevalence at baseline was 15% (145/1050) across all clusters, 304 with Pf the predominant species at 8-10%. The MMP clusters had higher baseline malaria prevalence with 305 92 positive individuals consisting of 45 Pf cases (49%), 39 Pv cases (42%), and 8 mixed Pf/Pv infections (9%) by PCR. Of the 53 PCR-positive cases at baseline in the FSAT clusters, there were 39 Pf cases 306 307 (73%), 13 Pv cases (25%) and 1 mixed Pf/Pv infection (2%). Withdrawals and losses to follow-up were not evenly distributed among study groups, with a higher proportion withdrawing from the FSAT group 308

- 309 (14.5%), compared to the MMP group (9.3%). Differences were nearly 2-fold higher after month 2 with
- 310 10.5% lost or withdrawn in the FSAT groups vs. 5.6% in MMP (**Supplemental Table 1**).

311

Cluster	Α	В	С	D	Е	F	G	н	Total
Treatment Group	FSAT	MMP	MMP	FSAT	FSAT	FSAT	MMP	MMP	
Uniform Assignment	sITU	sITU	ITU	ITU	ITU	sITU	sITU	ITU	
Baseline Endemicity	High	High	High	High	Low	Low	Low	Low	
Number Screened	151	150	134	129	121	139	140	150	1,114
Number Enrolled	143 (95)	142 (95)	130 (97)	125 (97)	115 (95)	133 (96)	128 (91)	134 (89)	1,050 (94)
Non-military	68 (48)	61 (43)	48 (37)	43 (34)	33 (29)	0 (0)	1 (1)	0 (0)	254 (24)
Children	32 (22)	32 (23)	33 (25)	13 (10)	10 (9)	0 (0)	0 (0)	0 (0)	120 (11)
Civilian adults	36 (25)	29 (20)	15 (12)	30 (24)	23 (20)	0 (0)	1 (1)	0 (0)	134 (13)
Positive for Malaria on Screening by PCR	29 (20)	29 (20)	28 (21)	17 (14)	4 (3)	3 (2)	22 (17)	13 (10)	145 (14)
<i>Pf</i> infection	23 (16)	17 (13)	12 (9)	12 (10)	2 (2)	2 (1)	11 (9)	5 (4)	84 (8)
Pv infection	5 (3)	11 (8)	11 (8)	5 (4)	2 (2)	1 (1)	9 (7)	8 (6)	53 (5)
Mixed <i>Pf/Pv</i> infection	1 (1)	1 (1)	5 (4)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)	9 (1)
G6PD Deficiency WHO Class I-III	15 (10)	17 (12)	25 (19)	15 (12)	13 (11)	25 (19)	23 (18)	27 (20)	160 (15)
G6PD Deficiency Primaquine-treated	5 (3)	16 (11)	25 (19)	2 (2)	2 (2)	1 (1)	22 (17)	24 (18)	97 (9.2%)
>10% Hemoglobin Drop at Day 3	0 (0)	3 (2)	6 (5)	0 (0)	1 (1)	0 (0)	3 (2)	1 (1)	14 (1.3%)

312

313 Table 1. Malaria elimination cluster characteristics. Composition of 8 geographically isolated clusters

randomized in the study including volunteer demographics, interventional assignments, baseline malaria prevalence,

315 G6PD-deficiency prevalence and primaquine treatments administered. Values are expressed as # (%) of those

enrolled in each cluster in rows 6 through 15. The number screened represented the population of each cluster, withthe number enrolled corresponding to intervention coverage (94% overall).

319 Treatment outcome by malaria species

320	All groups experienced rapid Pf malaria reduction within 30 days of study initiation (Fig 3A and
321	B). At the last follow up on Day 180, less than $<1\%$ of the study population had PCR-confirmed <i>Pf</i>
322	malaria, with Pv being the predominant species at 2-4% (Figures 2, 3 and 4). During the study period,
323	based on the detected malaria cases, the predicted unadjusted prevalence of P. falciparum was 11,048
324	episodes/100,000 population and the unadjusted prevalence of <i>P. vivax</i> was 15,238 episodes/100,000.
325	From Month 1 to study end, 11.0% (95% CI: 8.0-11.7%) of volunteers experienced Pv infection and
326	15.4% (CI: 11.5-15.7%) of volunteers experienced <i>Pf</i> infection at least once.
327	Pf malaria transmission was interrupted by both MMP and FSAT interventions. PCR-corrected
328	prevalence of <i>Pf</i> malaria declined from 9.9% at baseline to 0.4% on month 6 follow up (96% decline) for
329	MMP and from 7.6% to 0.97% (87.1% decline) in FSAT treatment group (Figure 3, Panel A-B). In
330	MMP, 16 of 51 (31%) subjects that were positive for <i>Pf</i> at enrollment presented with malaria recurrence
331	within their first two months of follow-up, with all 16 genotyped as recrudescences. All recurrent cases of
332	Pf in the MMP group were successfully treated with artesunate-mefloquine at the 1-month follow-up
333	visit. In FSAT, where all Pf-positive volunteers were treated with artesunate-mefloquine, 2/39 (5%) had
334	PCR-confirmed recurrence within their first month of follow-up, and all cases were confirmed to be new
335	infections. Volunteers assigned to the MMP arm experienced 2 cases of Pf in the last 3 months of follow-
336	up, compared to 4 cases of Pf in FSAT arm, during the same follow-up period.





338 Figure 3. PCR-adjusted malaria prevalence on the monthly follow up in MMP and FSAT. Rapid and sustained reductions in the number of Pf malaria cases were observed in MMP (green) and FSAT (orange) (Panel A-B). A 339 340 high rate of Pv malaria was detected for both interventions arms (Panel C-D) despite 270 mg total PO dose in MMP 341 arm (G6PD normal and G6PD deficient volunteers), over a 12 week period, and conventional doses of PQ in FSAT 342 arm (i.e., 15 mg x 14 days in G6PD normal volunteers and 45 mg weekly x 8 weeks in G6PD deficient volunteers). 343 Results are stratified between subjects that were positive at enrollment and tested positive at a follow-up time point 344 and subjects that were negative at enrollment but tested positive at a follow-up time point. Error bars reflect the 95% 345 confidence interval.

346 In contrast to Pf infections, ongoing Pv infections were observed in both treatment groups after enrollment during the study period. Despite rapid Pv decline in MMP, with no new cases detected during 347 the treatment period (Days 0-90), 45 of 481 (9.3%) MMP subjects tested positive for Pv parasitemia after 348 discontinuing prophylaxis within the 90-day follow-up period. In MMP subjects, 29% (13 of 45) of Pv 349 cases during the follow-up period were in subjects that were positive for Pv at enrollment (Figure 3, 350 351 Panel C). In FSAT, overall Pv rates were twice as high as in MMP subjects (cumulative 81 of 444, 352 18.2%) as in Figure 3, Panel D. Pv was more evenly distributed in the FSAT groups throughout the study period, with an average rate of 3.0% per month. Pv recurrences in individuals that were Pv positive 353 at baseline made up a larger percentage of total Pv cases in the MMP group compared to the FSAT group 354 (29% vs. 4.9%). The probability of Pv recurrence by 6 months if Pv-positive at baseline was similar for 355

356	both groups	(30% in MMP	and 29% in FSAT). In contrast to MMP,	only 4 of 81	Pv cases (4	4.9%))
-----	-------------	-------------	-----------------	------------------------	--------------	-------------	-------	---

- detected during follow-up in FSAT clusters were in *Pv*-positive individuals at enrollment.
- 358 The primary endpoint of the study was absolute risk reduction (ARR) for malaria at 6 months. A
- summary of absolute and relative risk reductions (RRR) are shown in Table 2. Overall there was a 68.7%
- 360 cumulative relative-risk reduction (RRR) for *Pf* malaria in MMP groups at day 90 (0.6% prevalence)
- 361 compared to FSAT (1.91%) or an absolute risk reduction (ARR) of 1.3%. RRR for *Pf* at day 180 in MMP
- 362 clusters (1.0%) was 61.5% with an ARR of 1.7% compared to FSAT (2.7%) (Table 2). Overall RRR for
- 363 *Pv* in MMP groups at day 90 (0% prevalence) was 100% compared to FSAT (9%) or an ARR of 9%.
- 364 RRR for Pv was 47.3% at day 180 in MMP clusters (6.7% prevalence) compared to FSAT (12.6%
- 365 prevalence) for an ARR of 6%.

366

A. Absolute (A	RR) ar	nd Relative Risk	Reduction (RF	RR) for	cumulative ma	laria posit	ivitv fo	or MMP \	s. FSAT
	, -			, -					

Pf	Day 90	Day 180	Pv	D90	D180
FSAT	1.91%	2.70%	FSAT	9.01%	12.61%
MMP	0.60%	1.04%	MMP	0.00%	6.65%
ARR	1.31%	1.66%	ARR	9.01%	5.96%
RRR	68.66%	61.54%	RRR	100.00%	47.25%
Fold-Reduction	3.2	2.6	Fold-Reduction	9	1.9

B. Absolute (ARR) and Relative Risk Reduction (RRR) for cumulative malaria positivity for ITU compared to sITU

Pf	Day 90	Day 180	Pv	D90	D180
all.sITU	1.74%	2.93%	all.sITU	6.28%	11.09%
all.ITU	0.66%	0.67%	all.ITU	2.24%	7.83%
ARR	1.08%	2.26%	ARR	4.04%	3.26%
RRR	62.13%	77.09%	RRR	64.35%	29.38%

C. Absolute (ARR) and Relative Risk Reduction (RRR) for cumulative malaria positivity for ITU vs sITU (FSAT only)

Pf	Day 90	Day 180	Pv	D90	D180
FSAT.sITU	2.29%	3.77%	FSAT.sITU	11.45%	17.15%
FSAT.ITU	1.43%	1.46%	FSAT.ITU	4.76%	7.32%
ARR	0.86%	2.30%	ARR	6.69%	9.84%
RRR	37.62%	61.14%	RRR	58.41%	57.35%

368 Table 2. Summary of absolute (ARR) and relative risk reductions (RRR) based on primary intervention

369 (MMP vs FSAT) and uniform treatment (ITU vs sITU). ARR and RRR are calculated based on cumulative

PCR-confirmed malaria positivity at months 3 and 6 over the course of the study for A. MMP with respect to FSAT;

- B. ITU with respect to sITU for both MMP and FSAT; C. ITU compared to sITU for FSAT only.
- 372
- Figure 4. shows gametocytes detected by microscopy for *Pf* (panel A, B) and *Pv* (panel C, D).
- No gametocytes were seen by microscopy in MMP clusters from months 1-6 for *Pf*, or months 1-4 for *Pv*.
- 375 While no microscopic *Pf* gametocytes were seen from months 2-6 in the FSAT group, *Pv* gametocytes
- 376 persisted throughout the observation period at a low level.







383 colored bars.

384 Diagnostic Parasite Detection

385 Participants were followed with parasitemia assessed monthly by rapid diagnostic test (RDT),

386 microscopy (Micro) and plasmodium species-specific polymerase chain reaction (PCR) for 180 days.

Diagnostic test results are shown in **Figure 5** for the MMP and FSAT groups (**5A-B**) and *Pf* and *Pv* for both groups (**5C-D**). Using PCR as the reference standard among 6,784 overall tests, microscopy was highly specific for both *Pf* (99.9%) and *Pv* (100%), but far more sensitive for *Pf* (84.3%) than *Pv* (39.0%). Microscopy was less sensitive than PCR, for both blood stage disease and gametocytes (3E-F). RDT was also highly specific for *Pf* (99.9%) and *Pv* (100%) compared to PCR but had poor sensitivity for *Pf* (69.4%) and virtually no sensitivity for *Pv* (0.5%).



Figure 5. Diagnostic detection of malaria. Prevalence of all malaria species at each monthly follow up is shown based on the three diagnostic methods (RDT, microscopy, and PCR) performed on each individual at each visit.
Participants were followed with parasitemia assessed monthly by rapid diagnostic test (RDT), microscopy (Micro) and plasmodium species-specific polymerase chain reaction (PCR) for 180 days. All RDT and Micro-positive cases were also PCR positive. Panels A. and B. compare detection rates between the (A) FSAT and (B) MMP groups.
Panels C. and D. compare detection rates for all volunteers for (C) *P. falciparum* and (D) *P. vivax*.

400 Effect of treated uniforms and endemicity on treatment outcome

401 Mixed-effects logistic regression was used to assess effects of uniform treatment and cluster

402 endemicity on treatment outcome. Endemicity and uniform treatments are expected to affect the rate of

403 acquiring *new* infections by affecting malaria vector exposure rates, but not rates of relapse or drug 404 treatment failure. As such, analysis included only subjects who were negative at enrollment for Pt, respectively, to assess the role of treatment and endemicity without confounding from treatment failure or 405 406 relapse. Overall, for *Pf* infections, FSAT had higher cumulative *Pf* positivity at 6 months than MMP 407 regardless of endemicity or uniform conditions (p < 0.01) (Figure 6A). Although uniform treatment had no statistically significant effect of on cumulative Pf positivity, the total number of Pf cases in the study 408 409 after Day 30 was low (16 total cases when excluding subjects positive at enrollment). There were no cases of *Pf* during follow-up in MMP subjects with treated uniforms. Cumulative *Pf* positivity in FSAT for 410 those with sham-treated uniforms (3.9%) was approximately double that of those with permethrin-treated 411 uniforms (1.9%; RRR 61%; ARR 2.3%). 412





Figure 6. Cumulative *Pf* and *Pv* positivity with respect to drug intervention, uniform treatment, and endemicity. Cumulative positivity from Day 0 to 180 is shown for *Pf*(A) and *Pv*(B); MMP (green bars) and FSAT (orange bars) treatment conditions, stratified by cluster endemicity (high vs. low) and uniform (sITU vs. ITU). 95% confidence interval error bars and statistical significance (* p < 0.05, ** p < 0.01, *** p < 0.001) are shown.



424	clusters. Stratifying by uniform type, FSAT subjects with sham-treated uniforms had almost 3-fold higher
425	cumulative Pv positivity than MMP subjects with sham-treated uniforms (p < 0.001). However, there
426	was no difference in Pv positivity between MMP and FSAT subjects wearing treated uniforms. FSAT
427	subjects wearing sham-treated uniforms had almost 2.5-fold higher Pv positivity at 3 (6.3%) and 6 months
428	(17%) than FSAT subjects wearing treated uniforms (2.2% and 7.3% respectively; RRR=57.4% and
429	ARR=9.8% at 6 months; $p < 0.01$). See Supplemental Table 2 for summary logistic regression results.

430

431 Malaria infection rate over time

432 Survival analysis was performed to evaluate rates of acquiring Pf and Pv infections over the course of the study. To ensure that the analysis was focused on new infections and not confounded by 433 relapse or treatment failure, malaria positive subjects at enrollment were excluded. Time-to-event 434 435 analysis was based on time to acquire the first documented Pf or Pv infection for each subject. The 436 analysis was stratified by endemicity, and included only high endemicity clusters for *Pf* as no new *Pf* infections were observed in low endemicity clusters. Pv survival curves were stratified by uniform 437 assignment (sITU vs ITU) after logistic regression analysis showed endemicity and uniform were 438 significantly associated with cumulative Pv positivity. 439



Figure 7. Survival curve to first *Pf* or *Pv* infection stratified by treatment. Survival curves are shown for *Pf*infection for FSAT (red) and MMP (blue) treatment conditions for in high endemicity clusters (A). Survival curves
for Pv infection in high and low endemicity clusters (B and C) are shown for FSAT+ITU (red), FSAT+sITU (green),
MMP+ITU (blue), and MMP+sITU (purple) conditions. 95% confidence intervals are shown as shaded colors
corresponding to each condition. There was only 1 low endemicity *Pf* case which is not graphically displayed.

448 Survival analysis showed significantly fewer *Pf* infections in the MMP than FSAT groups (Figure 7A, p<0.05), with no significant differences seen based on uniform treatment (not shown). For 449 the Pv survival curve in the high endemicity cluster, MMP treatment had significantly lower infection 450 rates than FSAT treatment ($p < 10^{-5}$). Treated uniforms showed significantly lower infection rates than 451 452 untreated uniforms (p < 0.05), with an interaction observed between treatment and uniform type (p < 0.05). Overall, in the high endemicity conditions, the FSAT+sITU condition performed significantly worse than 453 the other three conditions ($p < 10^{-7}$). The Pv survival curve in low endemicity clusters showed no 454 statistically significant difference in infection rates for treatment or uniform type. However, there was a 455 trend with higher infection rates for the FSAT+sITU condition than the other three. It is important to note, 456 in the Pv survival curves, that while FSAT infection rates remained steady, the MMP infection rate was 457 zero until D90, after which it increased to a level comparable to FSAT. 458 459

460 Safety

Of 1,050 volunteers enrolled, there were 1,237 adverse events (AEs) reported over the 6-month study 461 or 1.2 AEs per volunteer. The vast majority of AEs (88.0%) were classified as unlikely or not related to 462 463 study interventions. The most frequent AE was upper respiratory infection. Most AEs were mild to moderate in severity, and all resolved prior to study discharge. Study drugs were well tolerated, and there 464 465 were no AEs reported from ITU wear. There were 27 SAEs recorded during the study period. All were unrelated to the study interventions except for three that were classified as 'unlikely related' and 1 466 467 'possibly' related (new onset migraine headache which resulted in inpatient treatment). All volunteers with SAEs were followed until recovery or until their condition has stabilized. One volunteer was 468 diagnosed with breast cancer and was withdrawn from the study while receiving treatment. One 469

470 volunteer was withdrawn due to intolerance to DHA-PIP in MMP arm (vomiting). One volunteer died from causes unrelated to study interventions with causality assessed by the research monitor, an 471 472 independent review, and the ethics review board. 473 While there have been reports of clinically significant hemolysis observed following PQ 474 treatment even in G6PD normal individuals [32], no significant hemolysis occurred in G6PD-deficient volunteers taking primaquine during the study. All volunteers with moderate to severe G6PD deficiency 475 476 tolerated the modified 12 weekly doses of PQ without clinically significant hemolysis. There were 160 477 volunteers (15%) with G6PD-deficiency identified at screening. Of these, 97 (9.2%) took primaguine during the study, but only 14 (1.3%) had a hemoglobin decline >10% at day 3 (Table 1). No volunteers 478 479 had a hemoglobin drop >25% from baseline or required stopping therapy.

480 Discussion

At the time the study was designed in 2012, two alternative approaches to malaria elimination were 481 482 debated in Cambodia. The first, often termed Mass Drug Administration or MDA was thought to be the more effective approach. MDA offers the promise of lower costs, simplified logistics and improved 483 outcomes from sustained pressure on the parasite. However, perceptions surrounding compulsory drug 484 treatment for apparently healthy individuals with unclear risks with low malaria transmission in the GMS 485 486 raised ethical concerns. A large number of MDA studies have been conducted over the past 70 years with 487 tremendous variation in disease settings and approaches employed. A recent systematic review 488 highlighted difficulties comparing studies of varying designs, often complicated by a lack of well-defined 489 objectives [15]. Despite documented logistical challenges to implementation and lower effectiveness [20], a reactive 'screen and treat' approach (which we termed Focused Screening and Treatment or 490 491 FSAT) was thought more ethically palatable with only confirmed infections given drug treatment. Compared to prior studies that largely relied on less sensitive RDTs or microscopy, treatment in FSAT 492 493 group in this study was based on PCR results affording greater number of subjects getting treatment.

494 We sought to reconcile and recast these opposing views to malaria elimination, noting that human malaria often survives in the host undetected in latent, sub-clinical and sub-microscopic forms. Further, 495 496 in mixed-species transmission settings such as this one, treatment with blood stage antimalarials may not 497 interrupt disease transmissibility, and may in fact potentiate it [33]. Our use of the term monthly malaria 498 prophylaxis (MMP) was deliberate and intended to convey the full therapeutic intent. The MMP 499 addresses the four facets of affective treatment and malaria prevention, namely it (1) targets blood stage 500 infections; (2) reduces transmission risk posed by untreated infection; (3) lowers potential relapse from Pv 501 if treatment is co-administered with primaguine; and (4) lowers the risk of reinfection by reduction of 502 malaria burden. The treatments employed were intended to reduce and ultimately interrupt malaria 503 transmission with limited need for micromanagement required with a screening and treatment approach. 504 Namely frequent and repeated clinical evaluation, safety and molecular malaria diagnostic tests, and 505 therapeutic interventions. Insecticide-treated clothing was assessed for added benefit against day-biting 506 mosquitoes in endemic forested areas. 507 In the MMP regimen, the four therapeutic objectives above were achieved using

508 dihydroartemisin-piperaquine to treat acute parasitemia and provide suppressive chemoprophylaxis 509 (Objectives 1 and 4), and low-dose weekly primaguine to reduce transmission risk, eliminate or suppress 510 latent Pv infection (Objective 3), and provide causal liver-stage chemoprophylaxis (Objectives 2, 3, and 4). MMP groups reached zero PCR-detectable malaria parasitemia after 3 months of treatment. There 511 512 was no microscopic gametocytemia detected between Months 2-6 or blood-stage Pv by PCR between 513 Months 2-4. There were relative risk reductions (RRR) of 60-70% in cumulative Pf infection in the MMP group compared to FSAT over the course of the study, with a 1.6% absolute risk reduction (ARR). 514 The RRR of MMP relative to FSAT was 100% for Pv after the three-month intervention period, and 47% 515 516 through 6 months of follow-up with an ARR of 6%. Uptake of therapy was excellent, well-tolerated, and 517 coverage was high in this voluntary study. The primary drawback for MMP use was high baseline *Pf* 518 resistance to DP in Cambodia. The $\sim 30\%$ clinical failures required rescue therapy with A+M at Month 1, though all were cured and remained Pf negative thereafter. Future studies could investigate the use of 519

other drug combinations that are more effective for MDR *Pf* strains in Cambodia which would eliminatethe need for rescue treatments and monitoring for recrudescence.

522 In retrospect, the MMP results could have been achieved in this endemic community with less 523 frequent monitoring than a reactive screen-and-treat approach. MMP findings were in contrast to those 524 among the FSAT groups, particularly for Pv. The Pv parasitemia in MMP remained endemic at a rate of 525 2-4% throughout the study. This was despite a 4-fold lower baseline Pv infection rate in FSAT clusters 526 $(\sim 2\%)$ compared to MMP (>8%). During the follow-up period when MMP and FSAT groups had the 527 same screening/treatment regimen, malaria re-emerged in the MMP group, with Pv parasitemia detected within one month and Pf within three months after the intervention period. Although the study was not 528 529 powered to assess the effectiveness of insecticide-treated clothing, there was a statistically significant benefit against Pv infection in the FSAT but not MMP groups. Uniform treatment may provide additional 530 531 protection from malaria absent chemoprophylaxis as part of a screen-and-treat approach.

532 PCR was the definitive diagnostic method in the study, given high sensitivity for both Pf and Pv species compared to microscopy and RDTs. Microscopy had reasonable sensitivity for Pf(84.3%), but 533 534 poor sensitivity for Pv (39%). RDT had poor sensitivity for Pf (69.4%) and was almost completely 535 unable to detect Pv (0.5%), suggesting little diagnostic utility in elimination. While the PCR method used 536 was implementable from the reference lab supporting the field sites, the technical requirements and cost may render this approach challenging in some settings. Microscopy was able to detect gametocytes 537 538 unlike the other two methods, providing additional insights into transmission potential. However, gametocyte detection is more labor intensive, requiring longer microscopy reads covering more fields. 539 A recent systematic review identified at least 10 randomized trials evaluating malaria MDA in 540 high and low incidence settings [15]. In low-transmission settings using various regimens, both Pf and Pv541 542 burden were substantially reduced within 1-3 months. A prior systematic review of 32 studies from 2013 543 found that MDA led to sustained malaria reductions only in geographically isolated communities [17] 544 [32]. The key lesson from our study, and those preceding it, is the need for sustained intervention beyond three months, recognizing the difficulties comparing interventions from varied populations, risks 545

and settings [34]. Although impact is often relatively short-lived, pharmaceutically driven approaches to

546

547 malaria elimination appear to be more effective in low intensity transmission settings such as Cambodia 548 (1-10% prevalence). The most challenging elements to account for in any MDA study are movements in 549 and out of clusters. The clusters on the Cambodian-Thai border in our study were not truly 550 geographically isolated from malaria risk areas which tend to be occupational rather than residential. 551 Despite these challenges, the present study sustained parasite-free intervals in MMP clusters longer than 552 most prior efforts with 5 months before PCR-confirmed Pf reappeared in the study areas. Both 553 approaches were safe with the MMP approach superior to FSAT for parasite reductions, potential to 554 reduce resource requirements and scalability. 555 Cambodia has long been among the highest risk countries for antimalarial drug resistance for both *Pf*[35] and *Pv*[36]. Recent high rates of drug failure and tolerability considerations limited possible 556 557 elimination regimens [4, 37]. Given a lack of options for treatment when the study was implemented, a 558 monthly 3-day DP course was chosen as preferred chemoprophylaxis in the MMP clusters despite clinical 559 DP failures widely reported in the study area three years before study start [38]. At the time of the study, 560 Cambodia had recently replaced DP with A+M as first line Pf agent with a single 15mg dose of 561 primaguine to prevent transmission. The recent drug policy change was based on inverse resistance 562 patterns observed between DP and A+M in Northern Cambodia [35]. In line with these findings, there was a 32% initial DP failure rate in the MMP group in the first month, compared to no A+M regimen 563 564 failures in the FSAT group, and only 3 A+M recrudescences over 6 months. However, all treatment failures in the MMP group were successfully cured using A+M rescue therapy on month 1 follow-up. 565 While a 'failing regimen' ultimately managed to suppress *Pf* parasitemia there was a need to surveil for 566 567 recrudescences. Despite initial DP treatment failures, from an elimination standpoint DP+PQ treatment in 568 the MMP arm significantly outperformed FSAT using A+M treatment (RRR 60-70% for MMP compared 569 to FSAT for cumulative Pf during the study period). Our study was not alone in selecting DP as a 570 monthly blood stage elimination agent. The closest recent comparable study used monthly courses of DP with single low-dose PQ to eliminate Pf in Vietnam, Cambodia, Laos and Myanmar [39]. The study was 571

572 larger (~8,000 volunteers in 16 clusters) but coverage and acceptance were lower with fewer than half of 573 those treated completing 3 months of therapy. Despite the limitations, the approach worked with *Pf* 574 suppression persisting as long as one year in lower transmission areas. We did not find any significant 575 drug resistance at the study sites and observed that 9 of 10 cases of highly resistant *PfPailin* strain were 576 cured with initial therapy. To date there is limited evidence of a sustained MDA or prophylaxis approach 577 generating significant resistance.

578 Pv will likely be the greatest long-term obstacle to malaria elimination in Cambodia and SE Asia 579 [40]. Pv constituted 57% of overall malaria and 88% of malaria detected after initial enrollment in the 580 present study. Blood-stage Pv prevalence at baseline was comparable to Pf, and previously reported 581 relapse rates in the study area were as high as 70-80% in 2010 without primaguine radical cure [2]. Here, 582 MMP effectively suppressed or eliminated blood-stage Pv during the three-month intervention period with zero detected cases of Pv through Month 3, despite higher baseline Pv prevalence in MMP clusters 583 (8.4% compared to 2.7% in FSAT clusters). By contrast, monthly blood-stage Pv rates in the FSAT group 584 585 remained largely unchanged between 2-4% throughout the study period. There are few studies of Pv anti-586 relapse therapy in elimination settings [41]. Interpretation is confounded by the complexity of 587 distinguishing relapses, recrudescences, and reinfections [42]. In this study, it was impossible to determine whether MMP was effective against Pv because it cleared hypnozoites (PQ), interrupted 588 589 transmission (PQ), reduced reinfection (DP or PQ), or simply suppressed apparent blood-stage relapses (DP). The results based on the timing of infection suggest that MMP Pv recurrences were more likely to 590 591 be the result of relapses, while FSAT recurrences are more likely to be the result of reinfections (Supplemental Figure 2). The positive effect of ITU on Pv in FSAT supports the notion that ITU might 592 593 have helped interrupt Pv transmission in those settings. Although a higher percentage of MMP cases were 594 recurrences, there was an overall lower rate of Pv in the MMP group. The difference in interval between the two regimens may be due to a combination of factors – a higher reinfection rate of new Pv infections 595 596 in FSAT, suppression of detectable relapse during the intervention period in MMP, or both. However, it

is clear that the FSAT approach had little effect on *Pv* rates despite prompt administration of primaquine
radical cure following detection. This has implication for traditional malaria control programs, where
even if radical cure treatment is administered by DOT, it may be difficult to reduce *Pv* malaria in an
expeditious manner. Interpretation may be confounded by successive relapses of unrecognized
subclinical disease, indicating a higher proportion of the population affected at baseline than detectable
with current diagnostics.

603 A 22.5mg weekly primaguine dose was previously found to be effective in eliminating latent Pv in immigrants to Australia, and was the basis of the MMP regimen selected here [43]. Pv at enrollment 604 605 was the single greatest predictor of Pv positivity during the study using logistic regression, suggesting 606 that relapse played a major role in Pv infection rate. In both MMP and FSAT groups, approximately 30% 607 of individuals positive for Pv at enrollment had a Pv recurrence during the study. This compared to a 608 cumulative Pv rate of 7.4% in MMP and 15.6% in FSAT if Pv negative at enrollment. These findings 609 suggest that regardless of the different PO regimens used in MMP and FSAT, the cumulative 270 mg 610 dose of PQ employed here [43] may not be completely effective at preventing relapse. This is in line with 611 a recent study that found that PQ radical cure may only be 60-70% effective at preventing recurrences in 612 this setting [44]. Relapse efficacy may also be affected by a high proportion of intermediate metabolizer 613 genotypes for Cytochrome P450 2D6 polymorphisms [45]. Normal CYP2D6 activity is thought to be required for primaquine to be effective, though clinically significant reductions in primaquine 614 615 effectiveness have not been conclusively demonstrated in Cambodia.

Malaria elimination efforts are unlikely to be successful without suitable attention paid to the infectious gametocyte. Treatment of blood stage parasites can stimulate gametocytemia and increase transmission risk [33]. Few agents are capable of effectively treating stage V gametocytes in the human host to block mosquito transmission. While artemisinins are thought to have some antigametocidal activity, PQ is the most effective drug for this purpose [46]. A single 45mg dose of PQ administered with blood-stage therapy was a highly effective transmission-blocking agent at similar geographical areas as the present elimination study [47], eliminating circulating *Pf* gametocytes. It also prevented transmission

623 from patient blood samples to laboratory reared mosquitoes compared to no primaguine therapy. A lower 624 single 15mg dose is now widely recommended for transmission-blocking in combination with a blood 625 stage agent. While the MMP and FSAT groups were treated with PQ, the MMP group received a weekly 626 dose of PQ well in excess of the recommended transmission-blocking dose. The FSAT group received a 627 single transmission-blocking dose only if confirmed Pf positive or a radical curative dose only if Pvpositive, leaving subclinical gametocytemia untreated. In the MMP group, no microscopic Pv628 629 gametocytes were observed from Months 1-4 and no Pf gametocytes from Months 1 to 6. In the FSAT 630 group, while no Pf gametocytes were observed from Months 2-6, Pv gametocytes were seen in 50-67% of FSAT Pv infections throughout the entire 6-month observation period, suggesting onging Pv transmission 631 632 throughout the study. This may help explain why the addition of ITU was shown to be beneficial in 633 FSAT where transmission was never interrupted with the drug therapies alone. While gametocytemia was 634 not measured by PCR in the present study, microscopic gametocytemia is thought to have substantially 635 higher transmission risk than sub-microscopic gametocytemia [48]. Unfortunately, assessing community-636 level impact of transmission blocking agents is extremely challenging [46]. Further, though clusters were 637 geographically isolated by domicile, they were not necessarily isolated in the higher-risk occupational 638 areas. In Cambodia, risks are largely occupational – forested areas patrolled by military personnel in this case [49]. Individuals may have been exposed to infectious bites outside their dwelling clusters, and may 639 have transmitted disease there as well. As such we can only speculate on the relative contribution of 640 641 transmission blocking effects to the results.

One of the key features distinguishing the study from prior attempts at MDA was our intent to determine effectiveness of chemoprophylaxis in the military in the MMP group as a potential elimination approach, in combination with vector interventions (ITUs). This MDA approach is often considered to be ineffective given risks for adverse events and drug resistance pressure on the parasite [15]. However, some have argued for targeted chemoprophylaxis in forested malaria-endemic areas [49]. The results here largely support that recommendation, suggesting that safe, effective chemoprophylaxis including an 8-aminoquinoline is warranted in this low-transmission, high antimalarial drug resistance setting. A

combination of monthly 3-day treatment courses of DP and weekly low-dose PO safely led to a Relative 649 650 Risk Reduction of 100% over three months and 47% over six months. While it is impossible to assess the 651 individual contribution of DP and PQ in this study, inferences can be made based on known mechanisms 652 of action. The primary blood-stage post-treatment prophylactic effect was likely due to piperaquine, 653 despite substantial documentation of both clinical artemisinin and piperaquine resistance in this area [4]. While the DP combination initially failed to treat blood-stage disease in >30% of subjects, it appeared 654 655 sufficient to suppress submicroscopic blood-stage parasitemia during the remaining intervention period. 656 PO also has 'causal' liver-stage antimalarial activity against Pf and Pv, and there may have been some synergy between DP and PQ in suppressing blood and liver-stage parasitemia [49]. It is impossible to 657 658 distinguish the potential contributions or synergy of primaquine given the combination approach 659 employed. Others have found similar success with prophylaxis using more limited regimens. A 660 comparison of a monthly treatment course of artemether-lumefantrine showed significant risk reductions 661 compared to a multivitamin in forest-dwellers in Cambodia [50]. The large number of variables in the 662 study obviated establishing a control group for each of the interventions employed. 663 The study demonstrated the safety and tolerability of the pharmacologic approach to elimination. 664 High compliance was likely achieved through the use of DOT administration. DP is known to be safe and well-tolerated with the exception of elevated risk of QT-interval prolongation when given in a 665 666 compressed 2-day course [54]. The primary safety concern in the study was use of PQ in G6PD-deficient 667 volunteers. We were the first group to employ the 22.5mg/week PQ dose regimen in an endemic area as an elimination tool to prevent Pv relapse. The 22.5mg weekly dose chosen for the MMP group was based 668 on a previously safe, effective anti-relapse dose employed in Asian migrants to Australia [43]. PQ likely 669 670 provided anti-gametocyte activity and at least some degree of 'causal' liver-stage prophylaxis. The FSAT 671 groups used widely recommended PQ doses demonstrated to be safe in G6PD-deficiency for Pf 672 transmission blocking and/or Pv anti-relapse. In the MMP group, 16% of volunteers were G6PD deficient, comparable to prior observations [55]. Only 15% of subjects had hemoglobin declines of >10% 673 674 at day 3, none had declines of >25%, and none had to stop PQ treatment based on the pre-specified

individual halting rule of Grade 3 hemolysis. This is in line with expectations that even those with
relatively severe G6PD deficiency are able to tolerate PQ in low doses [56] and the modified weekly
regiment studied.

Vector-based interventions have long been a cornerstone of malaria control and containment. 678 679 Insecticide-treated bed nets (ITN) have historically been responsible for large reductions in malaria in sub-Saharan Africa. However, ITNs are less effective in Southeast Asia with predominantly day-biting 680 681 Anopheles species who breed in forested areas, and can be exophagic [49, 57]. Insecticide-treated clothing, typically using wash-resistant permethrin formulations, is often employed by military forces to 682 reduce vector-borne disease risk. The vast majority of vector-based interventions are tested based on their 683 684 efficacy against vector biting behavior. The study is also among the few to subject a vector-based intervention, particularly insecticide-treated uniforms and clothing to the rigor of a clinical trial of the 685 686 disease of interest. Only a handful of studies to date have assessed disease outcomes [58], despite 687 emerging concerns for malaria vector permethrin resistance in Africa [27]. Addition of insecticide-treated 688 uniforms (ITU) reduced malaria prevalence when paired with the FSAT but not MMP approaches, 689 suggesting this may be a good options for malaria elimination in select groups. Although difficult with 690 multiple interventions simultaneously employed to definitively distinguish relative contributions to outcomes, the results support ITU use in regions with day-biting vectors. While clothing and uniforms 691 692 were treated by the study team for this exercise, individual permethrin clothing treatment is relatively 693 easy to perform. ITU use resulted in significantly lower Pv positivity rates (p < 0.01) with RRR of ~60% for Pv compared to sITU. A similar effect size was seen for Pf with RRR of 40-60%. The latter 694 difference was not statistically significant given the small number of *Pf* infections in the study. It is 695 696 interesting to note that the observed effect size was consistent for both Pf and Pv. This was expected as 697 the two species share the same vector and should be equally affected by vector control measures. No 698 statistically significant difference was found in Pf and Pv infection rates for ITUs vs. sITUs in the MMP 699 group. It is possible that chemoprophylactic effects of the MMP regimen may have masked added 700 beneficial effects of uniform treatment.

701 This was the first study of a malaria elimination effort in the GMS carried out by and for a 702 military population. The present study demonstrates the effectiveness of the approach described in our 703 prior concept paper on malaria elimination by militaries in the GMS [28]. No elimination scheme can 704 work without a well-trained team able to carry out the complex set of clinical and laboratory activities 705 required. The joint team employed on this study included a large number of Royal Cambodian Armed 706 Forces medical and logistics personnel. The study created a basic Unit of Action for malaria elimination 707 easily replicated elsewhere. The Unit of Action included study physicians, nurses, lab technicians, data 708 analysts and a large cadre of soldier-medics training and working alongside the multinational AFRIMS 709 Malaria team. Achieving and sustaining the required operational tempo required for universal 710 quantitative G6PD testing, frequent diagnostic PCR testing and DOT would not have been possible 711 without significant RCAF support. The study demonstrated that elimination is not only possible within 712 GMS militaries but can be achieved by GMS militaries supporting national efforts. Despite the 713 achievement, those considering the approach must be mindful of the military ethical considerations, and 714 implement appropriate safeguards such as the use of non-military personnel as ombudsmen during the 715 consent process. Consent whether in the context of research or public health implementation, is essential 716 to establish and maintain trust.

717 There were several limitations to the study. First, despite randomization, the multiplicity of 718 simultaneous interventions makes it difficult to quantify relative contributions of individual interventions. 719 This was a deliberate choice. The goal of the study was to combine what were thought to be the most 720 regionally appropriate, safe, cost-effective elimination strategies available at the time rather than precisely 721 delineate individual contributions of each intervention. Second, assessment of potential reinfection for Pv722 was challenging, given the difficulties in distinguishing relapse, reinfection and recrudescence. Third, we 723 could not control for the effects of in- and out-migration. The former may have introduced additional 724 disease burden to clusters while the latter caused losses to follow-up from occupational reassignment. 725 Fourth, secular declines in parasite prevalence from either seasonal changes or ongoing control efforts in the region were also impossible to quantify. One or more no-intervention clusters may have helped 726

727 control for this, but were not undertaken for both ethical and practical considerations. To our knowledge, 728 study sites selected did not undergo other control measures beyond those of the study during the 729 observation period. Also, the study concluded during a time of the year generally considered to be a 730 higher malaria transmission period. The enrollment began during low malaria transmission (January) and 731 concluded during the rainy season (June) when malaria transmission in Cambodia typically increases 732 [59]. Seasonality would likely have contributed to a secular rise, rather than fall, in infection rates over 733 the course of the study if the control measures were ineffective. Finally, selection bias may have 734 influenced cluster composition, though unavoidable for practical reasons. This was mitigated by site selection based on several years of prior malaria data provided by the RCAF. However, past rates cannot 735 be relied on to predict actual transmission, and did not entirely do so here. 736

737

738 Conclusions

739 The all-encompassing approach to malaria elimination described here among mobile populations 740 on the Cambodian-Thai border demonstrated that a chemoprophylaxis strategy (MMP) was more effective 741 than a reactive-screen-and-treat approach (FSAT). However, FSAT intervention was improved by the addition of ITUs. The effects of MMP were longer lasting after the intervention was completed. This was 742 true for both Pf and Pv, though in this area of MDR Pf, follow-up surveillance and retreatment were 743 744 necessary for 30% of volunteers treated initially with DP. A weekly dose of 22.5mg primaquine was safe, well-tolerated, and appeared to potentiate DP prophylactic effects particularly against Pv. Individual 745 contributions of weekly PQ could not be established. FSAT was not effective in reducing Pv prevalence. 746 747 Insecticide-treated clothing appeared to provide additional benefit with the FSAT but not MMP approach. 748 The MMP approach may be more easily scaled to eliminate malaria given reduced need for diagnostic 749 assessments. The study informs a number of outstanding malaria elimination questions, and highlights 750 regional militaries as a potent force for malaria elimination in the GMS.

The study provided valuable insights into the ongoing fight against malaria in Cambodia and underscores the importance of multifaceted approaches tailored to local epidemiology. Cambodia's National Malaria Program can make significant strides towards malaria elimination in the future by integrating community engagement and empowerment, targeted chemoprophylaxis, vector control monitoring and implementation of ITUs for military populations, and evaluation into a comprehensive, adaptive approach.

757 References

 Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, Smithuis FM, Hlaing TM, Tun KM, van der Pluijm RW, et al: The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infect Dis 2017, 17:491-497.
 Lon C, Manning JE, Vanachayangkul P, So M, Sea D, Se Y, Gosi P, Lanteri C, Chaorattanakawee S,

- Sriwichai S, et al: Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine
 for uncomplicated malaria in military personnel in northern Cambodia: an open-label
 randomized trial. *PLoS One* 2014, **9**:e93138.
- Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Artemisinin Resistance in
 Cambodia 1 Study C: Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J
 Med 2008, 359:2619-2620.
- Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, Se Y, Chann S, Ittiverakul
 M, Sia-ngam P, et al: Dihydroartemisinin-piperaquine failure associated with a triple mutant
 including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis 2015,
 15:683-691.
- 5. Wongsrichanalai C, Meshnick SR: Declining artesunate-mefloquine efficacy against falciparum
 malaria on the Cambodia-Thailand border. *Emerg Infect Dis* 2008, 14:716-719.
- Phương VT: New initiatives launched to end malaria in ASEAN. In *Vietnam*. Hanoi,
 Vietnam2018.
- 777 7. Countries in WHO South-East Asia Region renew commitment to eliminate malaria by 2030
 778 [<u>https://www.who.int/southeastasia/news/detail/05-05-2022-countries-in-who-south-east-asia-</u>
 779 region-renew-commitment-to-eliminate-malaria-by-2030]
- Sovannaroth S, Ngor P, Khy V, Dunn JC, Burbach MK, Peng S, Mak S, Siv K, Manzoni G, Guintran
 JO, et al: Accelerating malaria elimination in Cambodia: an intensified approach for targeting
 at-risk populations. *Malar J* 2022, **21**:209.
- 9. Smith C, Whittaker M: Beyond mobile populations: a critical review of the literature on malaria
 and population mobility and suggestions for future directions. *Malar J* 2014, 13:307.
- Bhumiratana A, Intarapuk A, Sorosjinda-Nunthawarasilp P, Maneekan P, Koyadun S: Border
 malaria associated with multidrug resistance on Thailand-Myanmar and Thailand-Cambodia
 borders: transmission dynamic, vulnerability, and surveillance. *Biomed Res Int* 2013,
 2013:363417.

789 11. Wangroongsarb P, Sudathip P, Satimai W: Characteristics and malaria prevalence of migrant 790 populations in malaria-endemic areas along the Thai-Cambodian border. Southeast Asian J 791 Trop Med Public Health 2012, 43:261-269. 792 12. Bustos MD, Wongsrichanalai C, Delacollette C, Burkholder B: Monitoring antimalarial drug 793 efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010. 794 Southeast Asian J Trop Med Public Health 2013, 44 Suppl 1:201-230; discussion 306-207. 795 Delacollette C, D'Souza C, Christophel E, Thimasarn K, Abdur R, Bell D, Dai TC, Gopinath D, Lu S, 13. 796 Mendoza R, et al: Malaria trends and challenges in the Greater Mekong Subregion. Southeast 797 Asian J Trop Med Public Health 2009, 40:674-691. 798 Nofal SD, Peto TJ, Adhikari B, Tripura R, Callery J, Bui TM, von Seidlein L, Pell C: How can 14. 799 interventions that target forest-goers be tailored to accelerate malaria elimination in the 800 Greater Mekong Subregion? A systematic review of the qualitative literature. Malar J 2019, 801 18:32. 802 15. Schneider ZD, Shah MP, Boily MC, Busbee AL, Hwang J, Lindblade KA, Gutman JR: Mass Drug 803 Administration to Reduce Malaria Transmission: A Systematic Review and Meta-Analysis. Am J 804 Trop Med Hyg 2023. 805 16. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J: Mass drug administration for 806 malaria. Cochrane Database Syst Rev 2013, 2013:CD008846. 807 17. Newby G, Hwang J, Koita K, Chen I, Greenwood B, von Seidlein L, Shanks GD, Slutsker L, Kachur 808 SP, Wegbreit J, et al: Review of mass drug administration for malaria and its operational 809 challenges. Am J Trop Med Hyg 2015, 93:125-134. 810 18. Kondrashin A, Baranova AM, Ashley EA, Recht J, White NJ, Sergiev VP: Mass primaguine 811 treatment to eliminate vivax malaria: lessons from the past. Malar J 2014, 13:51. 812 19. Brady OJ, Slater HC, Pemberton-Ross P, Wenger E, Maude RJ, Ghani AC, Penny MA, Gerardin J, 813 White LJ, Chitnis N, et al: Role of mass drug administration in elimination of Plasmodium 814 falciparum malaria: a consensus modelling study. Lancet Glob Health 2017, 5:e680-e687. 815 20. Searle KM, Hamapumbu H, Lubinda J, Shields TM, Pinchoff J, Kobayashi T, Stevenson JC, Bridges 816 DJ, Larsen DA, Thuma PE, et al: Evaluation of the operational challenges in implementing 817 reactive screen-and-treat and implications of reactive case detection strategies for malaria 818 elimination in a region of low transmission in southern Zambia. Malar J 2016, 15:412. 819 21. Newby G, Cotter C, Roh ME, Harvard K, Bennett A, Hwang J, Chitnis N, Fine S, Stresman G, Chen 820 I, et al: Testing and treatment for malaria elimination: a systematic review. Malar J 2023, 821 **22:**254. 822 22. Sanann N, Peto TJ, Tripura R, Callery JJ, Nguon C, Bui TM, Nofal SD, von Seidlein L, Lek D, 823 Dondorp AM, et al: Forest work and its implications for malaria elimination: a qualitative 824 study. Malar J 2019, 18:376. 825 23. Cook J, Xu W, Msellem M, Vonk M, Bergstrom B, Gosling R, Al-Mafazy AW, McElroy P, Molteni F, 826 Abass AK, et al: Mass screening and treatment on the basis of results of a Plasmodium 827 falciparum-specific rapid diagnostic test did not reduce malaria incidence in Zanzibar. J Infect 828 Dis 2015, 211:1476-1483. 829 24. Kern SE, Tiono AB, Makanga M, Gbadoe AD, Premji Z, Gaye O, Sagara I, Ubben D, Cousin M, 830 Oladiran F, et al: Community screening and treatment of asymptomatic carriers of Plasmodium 831 falciparum with artemether-lumefantrine to reduce malaria disease burden: a modelling and 832 simulation analysis. Malar J 2011, 10:210. 833 Scott CA, Yeshiwondim AK, Serda B, Guinovart C, Tesfay BH, Agmas A, Zeleke MT, Guesses GS, 25. 834 Ayenew AL, Workie WM, et al: Mass testing and treatment for malaria in low transmission 835 areas in Amhara Region, Ethiopia. Malar J 2016, 15:305.

836 26. Pfeffer DA, Ley B, Howes RE, Adu P, Alam MS, Bansil P, Boum Y, 2nd, Brito M, Charoenkwan P, 837 Clements A, et al: Correction: Quantification of glucose-6-phosphate dehydrogenase activity 838 by spectrophotometry: A systematic review and meta-analysis. PLoS Med 2020, 17:e1003311. 839 27. Yusuf MA, Oshaghi MA, Vatandoost H, Hanafi-Bojd AA, Enayati A, Jalo RI, Aminu A, Daneji IM: 840 Current Status of Insecticide Susceptibility in the Principal Malaria Vector, Anopheles gambiae 841 in Three Northern States of Nigeria. J Arthropod Borne Dis 2021, 15:196-206. 842 Manning JE, Satharath P, Gaywee J, Lopez MN, Lon C, Saunders DL: Fighting the good fight: the 28. 843 role of militaries in malaria elimination in Southeast Asia. Trends Parasitol 2014, 30:571-581. 844 29. Manning J, Lon C, Spring M, Wojnarski M, Somethy S, Chann S, Gosi P, Soveasna K, Sriwichai S, 845 Kuntawunginn W, et al: Cluster-randomized trial of monthly malaria prophylaxis versus 846 focused screening and treatment: a study protocol to define malaria elimination strategies in 847 Cambodia. Trials 2018, 19:558. 848 30. Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, Brown KN, Viriyakosol S: Biased distribution 849 of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R 850 Soc Trop Med Hyg 1999, 93:369-374. 851 31. Campbell MK, Thomson S, Ramsay CR, MacLennan GS, Grimshaw JM: Sample size calculator for 852 cluster randomized trials. Comput Biol Med 2004, 34:113-125. 853 32. Chu CS, Bancone G, Moore KA, Win HH, Thitipanawan N, Po C, Chowwiwat N, Raksapraidee R, 854 Wilairisak P, Phyo AP, et al: Haemolysis in G6PD Heterozygous Females Treated with 855 Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative 856 Regimens. PLoS Med 2017, 14:e1002224. Mason DP, McKenzie FE: Blood-stage dynamics and clinical implications of mixed Plasmodium 857 33. 858 vivax-Plasmodium falciparum infections. Am J Trop Med Hyg 1999, 61:367-374. 859 34. Kagaya W, Gitaka J, Chan CW, Kongere J, Md Idris Z, Deng C, Kaneko A: Malaria resurgence after 860 significant reduction by mass drug administration on Ngodhe Island, Kenya. Sci Rep 2019, 861 9:19060. 862 35. Chaorattanakawee S, Saunders DL, Sea D, Chanarat N, Yingyuen K, Sundrakes S, Saingam P, Buathong N, Sriwichai S, Chann S, et al: Ex Vivo Drug Susceptibility Testing and Molecular 863 864 Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest 865 Emerging Piperaquine Resistance. Antimicrob Agents Chemother 2015, 59:4631-4643. 866 36. Chaorattanakawee S, Lon C, Chann S, Thay KH, Kong N, You Y, Sundrakes S, Thamnurak C, 867 Chattrakarn S, Praditpol C, et al: Measuring ex vivo drug susceptibility in Plasmodium vivax isolates from Cambodia. Malar J 2017, 16:392. 868 869 37. Wojnarski M, Lon C, Vanachayangkul P, Gosi P, Sok S, Rachmat A, Harrison D, Berjohn CM, Spring M, Chaoratanakawee S, et al: Atovaquone-Proguanil in Combination With Artesunate to 870 871 Treat Multidrug-Resistant P. falciparum Malaria in Cambodia: An Open-Label Randomized 872 Trial. Open Forum Infect Dis 2019, 6:ofz314. 873 38. Saunders DL, Vanachayangkul P, Lon C, Program USAMMR, National Center for Parasitology E, 874 Malaria C, Royal Cambodian Armed F: Dihydroartemisinin-piperaguine failure in Cambodia. N 875 Engl J Med 2014, **371:**484-485. 876 39. von Seidlein L, Peto TJ, Landier J, Nguyen TN, Tripura R, Phommasone K, Pongvongsa T, Lwin KM, 877 Keereecharoen L, Kajeechiwa L, et al: The impact of targeted malaria elimination with mass 878 drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial. PLoS 879 Med 2019, 16:e1002745. 880 40. Siv S, Roca-Feltrer A, Vinjamuri SB, Bouth DM, Lek D, Rashid MA, By NP, Popovici J, Huy R, 881 Menard D: Plasmodium vivax Malaria in Cambodia. Am J Trop Med Hyg 2016, 95:97-107. 882 41. Shah MP, Westercamp N, Lindblade KA, Hwang J: Mass Relapse Prevention to Reduce 883 **Transmission of Plasmodium vivax-A Systematic Review.** Am J Trop Med Hyg 2023.

884 Lin JT, Hathaway NJ, Saunders DL, Lon C, Balasubramanian S, Kharabora O, Gosi P, Sriwichai S, 42. 885 Kartchner L, Chuor CM, et al: Using Amplicon Deep Sequencing to Detect Genetic Signatures of 886 Plasmodium vivax Relapse. J Infect Dis 2015, 212:999-1008. 887 43. Grimmond TR, Cameron AS: Primaguine-chloroguine prophylaxis against malaria in Southeast-888 Asian refugees entering South Australia. Med J Aust 1984, 140:322-325. 889 44. Llanos-Cuentas A, Lacerda MVG, Hien TT, Velez ID, Namaik-Larp C, Chu CS, Villegas MF, Val F, 890 Monteiro WM, Brito MAM, et al: Tafenoquine versus Primaguine to Prevent Relapse of 891 Plasmodium vivax Malaria. N Engl J Med 2019, 380:229-241. 892 45. Spring MD, Lon C, Sok S, Sea D, Wojnarski M, Chann S, Kuntawunginn W, Kheang Heng T, Nou S, 893 Arsanok M, et al: Prevalence of CYP2D6 Genotypes and Predicted Phenotypes in a Cohort of 894 Cambodians at High Risk for Infections with Plasmodium vivax. Am J Trop Med Hyg 2020, 895 103:756-759. 896 46. Delves MJ, Angrisano F, Blagborough AM: Antimalarial Transmission-Blocking Interventions: 897 Past, Present, and Future. Trends Parasitol 2018, 34:735-746. 898 47. Lin JT, Lon C, Spring MD, Sok S, Chann S, Ittiverakul M, Kuntawunginn W, My M, Thay K, Rahman 899 R, et al: Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum 900 transmission in Cambodia: An open-label randomized trial. PLoS One 2017, 12:e0168702. 901 48. Lin JT, Saunders DL, Meshnick SR: The role of submicroscopic parasitemia in malaria 902 transmission: what is the evidence? Trends Parasitol 2014, 30:183-190. 903 49. von Seidlein L, Peto TJ, Tripura R, Pell C, Yeung S, Kindermans JM, Dondorp A, Maude R: Novel 904 Approaches to Control Malaria in Forested Areas of Southeast Asia. Trends Parasitol 2019, 905 **35:**388-398. 906 50. Tripura R, von Seidlein L, Sovannaroth S, Peto TJ, Callery JJ, Sokha M, Ean M, Heng C, Conradis-907 Jansen F, Madmanee W, et al: Antimalarial chemoprophylaxis for forest goers in southeast 908 Asia: an open-label, individually randomised controlled trial. Lancet Infect Dis 2023, 23:81-90. 909 51. Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, Lievens M, Leboulleux D, 910 Njuguna P, Peshu N, et al: Four-year efficacy of RTS,S/AS01E and its interaction with malaria 911 exposure. N Engl J Med 2013, 368:1111-1120. 912 52. Datoo MS, Dicko A, Tinto H, Ouedraogo JB, Hamaluba M, Olotu A, Beaumont E, Ramos Lopez F, 913 Natama HM, Weston S, et al: Safety and efficacy of malaria vaccine candidate R21/Matrix-M in 914 African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 2024, 403:533-915 544. 916 53. Maude RJ, Socheat D, Nguon C, Saroth P, Dara P, Li G, Song J, Yeung S, Dondorp AM, Day NP, et 917 al: Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: 918 primaguine, mass drug administration and artemisinin resistance. PLoS One 2012, 7:e37166. 919 54. Manning J, Vanachayangkul P, Lon C, Spring M, So M, Sea D, Se Y, Somethy S, Phann ST, Chann S, 920 et al: Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of 921 dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged 922 corrected QT interval. Antimicrob Agents Chemother 2014, 58:6056-6067. 923 55. Wojnarski B, Lon C, Sea D, Sok S, Sriwichai S, Chann S, Hom S, Boonchan T, Ly S, Sok C, et al: 924 Evaluation of the CareStart glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test 925 in the field settings and assessment of perceived risk from primaquine at the community level 926 in Cambodia. PLoS One 2020, 15:e0228207. 927 White NJ: Primaguine to prevent transmission of falciparum malaria. Lancet Infect Dis 2013, 56. 928 13:175-181. 929 57. Cheng B, Htoo SN, Mhote NPP, Davison CM: A systematic review of factors influencing 930 participation in two types of malaria prevention intervention in Southeast Asia. Malar J 2021, 931 **20:**195.

- Soto J, Medina F, Dember N, Berman J: Efficacy of permethrin-impregnated uniforms in the
 prevention of malaria and leishmaniasis in Colombian soldiers. *Clin Infect Dis* 1995, 21:599 602.
- 935 59. Chhim S, Piola P, Housen T, Herbreteau V, Tol B: Malaria in Cambodia: A Retrospective Analysis
 936 of a Changing Epidemiology 2006-2019. Int J Environ Res Public Health 2021, 18.
- 937
- 938
- 939

940 Acknowledgements

We are grateful to the study participants and communities who participated in and supported this study.We also thank the Royal Cambodian Armed Forces for their support.

943 Disclaimer

944 The views expressed in this article are those of the authors and do not reflect the official policy of the US

- 945 Department of the Army, US Department of Defense, the US Government or the Royal Government of
- 946 Cambodia.

947 Author contributions

- 948 Study design: DLS, JEM, PS, JTL, SS, WK, PG
- 949 Data collection: All
- 950 Data analysis: MW, SC, TB, SS, PG, DLS, WK, TK, PG
- Data interpretation and study conclusions: TB, MW, SC, SS, PG, JTL, DLS, JEM, MS, PV
- 952 Writing manuscript: MW, DLS, SC,
- 953 Editing manuscript: DLS, SC, SS, JEM, JTL, MS
- All authors read and approved the final manuscript.
- 955 Funding
- 956 The study was supported by a grant from the Bill and Melinda Gates Foundation and the Defense
- 957 Malaria Assistance Program. The funding source played no role in the drafting, review or approval of the
- 958 manuscript.
- 959 Availability of data and materials
- 960 The dataset supporting the conclusions of this article is included within the article and its additional files.
- 961 Declarations
- 962 Ethics approval and consent to participate

- 963 This study was approved by the Institutional Review Board at the Walter Reed Army Institute of
- 964 Research and the Cambodian National Ethics Committee on Human Research. All study participants
- 965 provided written study consent to participate.
- 966 Consent for publication
- 967 All study subjects agreed to publication of the study results in the medical literature without their
- 968 identity at consent prior to participation.
- 969 *Competing interests*
- 970 The authors declare that they have no competing interests.

971 Supplemental Material

972

	Time	MMP W	MMP LTF	MMP ToT	MMP %	FSAT W	FSAT LTF	FSAT ToT	FSAT %	TOT W	TOT LTF	тот	ToT %
	D1-30	7	1	8	1.5%	5	1	6	1.2%	12	2	14	1.3%
	D31-60	12	0	12	2.2%	11	4	15	2.9%	23	4	27	2.6%
	D61-90	4	1	5	0.9%	9	8	17	3.3%	13	9	22	2.1%
	D91-180	19	6	25	4.7%	25	12	37	7.2%	44	18	62	5.9%
3	Total	42	8	50	9.3%	50	25	75	14.5%	92	33	125	11.9%

974 Supplemental Table 1. Withdrawals (W) and losses to follow-up (LTF) over time by treatment group

975 and total volunteers (TOT).

976

Pf - high ende	emicity			95%	o C.I.	95% C.I.			
	Total	<i>Pf</i> Positive	Percent	lower	upper	Odds- Ratio	lower	upper	p-value
FSAT.sITU	97	8	8.2%	3.6%	15.6%	Reference			
FSAT.ITU	105	4	3.8%	1.1%	9.5%	0.464	0.135	1.593	n.s.
MMP.sITU	107	5	4.7%	1.5%	10.6%	0.545	0.172	1.727	n.s.
MMP.ITU	106	0	0.0%	0.0%	3.4%	-	-	-	-

Pv - high ende	emicity			95%	C.I .	95% C.I.				
	Total	<i>Pv</i> Positive	Percent	lower	upper	Odds- Ratio	lower	upper	p-value	
FSAT.sITU	113	30	26.5%	18.7%	35.7%	Reference				
FSAT.ITU	105	12	11.4%	6.1%	19.1%	0.357	0.172	0.742	0.0056	
MMP.sITU	115	12	10.4%	5.5%	17.5%	0.322	0.155	0.668	0.0023	
MMP.ITU	108	10	9.3%	4.5%	16.4%	0.282	0.13	0.612	0.0013	

Pv - low ende	emicity			95%	o C.I.	95% C.I.				
	Total	<i>Pv</i> Positive	Percent	lower	upper	Odds- Ratio	lower	upper	p-value	
FSAT.sITU	122	12	9.8%	5.2%	16.6%	Reference				
FSAT.ITU	93	4	4.3%	1.2%	10.7%	0.444	0.137	1.44	n.s.	
MMP.sITU	106	2	1.9%	0.2%	6.7%	0.192	0.042	0.889	n.s.	
MMP.ITU	111	8	7.2%	3.2%	13.7%	0.777	0.301	2.01	n.s.	

977

978 Supplemental Table 2. Summary logistic regression analysis results. All comparisons are made with respect to
979 FSAT randomized to sham-treated uniforms (FSAT+sITU). In high Pf-endemicity clusters, both FSAT with treated
980 uniforms and MMP with untreated uniforms had 2-fold less risk for malaria infection (ns). In high Pv endemicity
981 clusters, FSAT with treated uniforms or MMP with or without treated uniforms had a roughly 3-fold significant
982 decrease (95% CI of 1.5-fold to 6.5-fold) in malaria risk (p < 0.01). There was a trend toward decrease in Pv risk in
983 low endemicity clusters associated with treated uniforms or MMP (ns).

986 Recurrent *Pv* infection during study follow-up

987 Nearly all cases of malaria recurrence (26/30, 86%) after the first monthly follow-up were due to Pv malaria (Fig 3C and D). There were 13 Pv recurrences in FSAT treatment group and 13 cases in 988 989 MMP. These Pv recurrences may represent relapses or new infections. Logistic regression revealed that recurrence of Pv in MMP was associated with diagnosis of Pv on enrollment (p<0.001) and lower weekly 990 991 PQ dose (<5mg/kg/total dose; p<0.001). Among the volunteers with at least one episode of Pv malaria, 992 the cumulative risk of Pv recurrence (Kaplan-Meier analysis) was 8% in MMP arm and 17% in FSAT within 150 days of follow up (Supplemental Figure 1A). There were three notable distinctions between 993 Pv recurrences in the MMP and FSAT treatment groups. First, in the MMP group, 100% (13/13) of cases 994 995 of Pv recurrence were in individuals that tested positive for Pv at enrollment which was significantly 996 higher than the 31% (4/13) of cases in FSAT (p < 0.001). Second, in the FSAT treatment group, subjects 997 wearing sITUs were approximately three times as likely to experience a Pv recurrence compared to 998 subjects wearing ITUs (p < 0.01), while in the MMP group there was no significant difference with 999 respect to uniform. Third, the mean interval between the first and second Pv infection was significantly longer for MMP, at 166 days (s.d. 23 days) than for FSAT, at 108 days (s.d. 31 days) ($p < 10^{-4}$ 1000



Supplemental Figure 1. Recurrent *Pv* infections in subjects with at least one *Pv* infection. A) Survival curve to
a second *Pv* infection from the first *Pv* infection for all subjects with at least one documented *Pv* infection in the
FSAT (red) and MMP (blue) treatment groups. B) Time interval between observing the first and second Pv infection
for all subjects that had two documented *Pv* infections in the study. MMP (blue) and FSAT (red) treatment groups
are shown as well sITU (open symbol) and ITU (closed symbol).